Natixis Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Natixis Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.3M	Sell	268,328 -55,706	-17%	-$922K	﹤0.01%	967
2026 Q1	$6M	Buy	324,034 +96,280	+42%	+$1.69M	0.01%	795
2025 Q4	$3.55M	Sell	227,754 -252,618	-53%	-$3.61M	0.01%	900
2025 Q3	$7.03M	Buy	480,372 +26,845	+6%	+$399K	0.01%	758
2025 Q2	$7.01M	Buy	453,527 +33,249	+8%	+$491K	0.01%	737
2025 Q1	$6.25M	Sell	420,278 -58,301	-12%	-$817K	0.01%	759
2024 Q4	$6.34M	Buy	478,579 +21,539	+5%	+$296K	0.01%	762
2024 Q3	$6.5M	Sell	457,040 -11,071	-2%	-$157K	0.01%	767
2024 Q2	$6.06M	Sell	468,111 -214,178	-31%	-$2.84M	0.01%	748
2024 Q1	$9.48M	Buy	682,289 +26,185	+4%	+$381K	0.02%	625
2023 Q4	$9.36M	Sell	656,104 -15,783	-2%	-$224K	0.02%	573
2023 Q3	$10.4M	Buy	671,887 +10,857	+2%	+$168K	0.03%	499
2023 Q2	$10.4M	Sell	661,030 -29,398	-4%	-$482K	0.03%	515
2023 Q1	$11.4M	Sell	690,428 -26,061	-4%	-$415K	0.04%	455
2022 Q4	$11.2M	Sell	716,489 -50,954	-7%	-$712K	0.04%	444
2022 Q3	$9.95M	Buy	767,443 +149,114	+24%	+$2.07M	0.04%	434
2022 Q2	$8.68M	Buy	618,329 +6,920	+1%	+$98.8K	0.04%	473
2022 Q1	$8.76M	Buy	611,409 +207,871	+52%	+$3.05M	0.03%	502
2021 Q4	$5.5M	Sell	403,538 -166,334	-29%	-$2.33M	0.02%	634
2021 Q3	$9.33M	Buy	569,872 +43,941	+8%	+$738K	0.04%	446
2021 Q2	$8.85M	Buy	525,931 +13,455	+3%	+$229K	0.04%	436
2021 Q1	$9.36M	Buy	512,476 +192,940	+60%	+$3.47M	0.05%	408
2020 Q4	$5.82M	Buy	319,536 +36,031	+13%	+$632K	0.03%	499
2020 Q3	$5.06M	Buy	283,505 +16,394	+6%	+$299K	0.03%	519
2020 Q2	$4.79M	Sell	267,111 -6,126	-2%	-$110K	0.03%	530
2020 Q1	$4.15M	Buy	273,237 +61,589	+29%	+$1.12M	0.03%	511
2019 Q4	$4.17M	Buy	211,648 +24,083	+13%	+$461K	0.03%	596
2019 Q3	$3.23M	Buy	187,565 +46,118	+33%	+$798K	0.03%	642
2019 Q2	$2.5M	Sell	141,447 -2,277	-2%	-$41.4K	0.02%	707
2019 Q1	$2.93M	Buy	143,724 +57,798	+67%	+$1.16M	0.03%	628
2018 Q4	$1.45M	Buy	+85,926	New	+$1.45M	0.01%	803

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Natixis Advisors's TAK Position: Q2 2026 in Review

Natixis Advisors reduced its Takeda Pharmaceutical (TAK) stake by 17% in Q2 2026, selling an estimated $922K and leaving 268,328 shares worth $4.3M. The position accounts for ﹤0.01% of the portfolio, ranked #967.

Natixis Advisors first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $11.4M in Q1 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Natixis Advisors held 268,328 shares of Takeda Pharmaceutical worth $4.3M as of Q2 2026.
Natixis Advisors sold 55,706 Takeda Pharmaceutical shares in Q2 2026, an estimated $922K.
Takeda Pharmaceutical made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #967 holding.
Natixis Advisors first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
Natixis Advisors's Takeda Pharmaceutical position peaked at $11.4M in Q1 2023.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.